RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+21.75%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.87B
AUM Growth
+$3.87B
(+13%)
Cap. Flow
+$152M
Cap. Flow
% of AUM
3.92%
Top 10 Holdings %
Top 10 Hldgs %
35.18%
Holding
134
New
3
Increased
60
Reduced
11
Closed
5
Top Buys
| 1 |
Immunocore
IMCR
|
$38.6M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$36.8M |
| 3 |
Akero Therapeutics
AKRO
|
$23.5M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$20.7M |
| 5 |
Gossamer Bio
GOSS
|
$19M |
Top Sells
Sector Composition
| 1 | Healthcare | 96.8% |
| 2 | Consumer Staples | 0.91% |
| 3 | Industrials | 0.67% |
| 4 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
BioMarin Pharmaceuticals
BMRN
$11.3B
| $22.4M | 0.58% |
264,500
| – | – |
|
52
BioCryst Pharmaceuticals
BCRX
$1.74B
| $21.6M | 0.56% |
1,712,507
+251,416
| +17% | +$3.17M |
|
53
Cytokinetics
CYTK
$5.98B
| $21.5M | 0.55% |
443,000
+43,000
| +11% | +$2.08M |
|
54
Madrigal Pharmaceuticals
MDGL
$9.7B
| $20.6M | 0.53% |
317,485
| – | – |
|
|
VERV
55
DELISTED
Verve Therapeutics
VERV
| $19.2M | 0.5% |
558,837
+54,800
| +11% | +$1.88M |
|
|
56
Gossamer Bio
GOSS
$587M
| $19M | 0.49% |
+1,586,962
| New | +$19M |
|
57
Exact Sciences
EXAS
$9.33B
| $18.8M | 0.49% |
578,600
+5,900
| +1% | +$192K |
|
58
CONMED
CNMD
$1.64B
| $18.7M | 0.48% |
233,000
+10,000
| +4% | +$802K |
|
59
Aura Biosciences
AURA
$394M
| $18.4M | 0.48% |
1,015,757
+6,943
| +0.7% | +$126K |
|
60
Legend Biotech
LEGN
$6.64B
| $18.4M | 0.47% |
450,466
+94,899
| +27% | +$3.87M |
|
61
Dynavax Technologies
DVAX
$1.19B
| $17.6M | 0.45% |
1,683,358
+1,900
| +0.1% | +$19.8K |
|
|
OLK
62
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $17.5M | 0.45% |
1,445,000
+213,200
| +17% | +$2.59M |
|
63
Warby Parker
WRBY
$3.08B
| $17.5M | 0.45% |
1,309,475
+35,975
| +3% | +$480K |
|
64
Immatics
IMTX
$662M
| $16.8M | 0.43% |
1,681,224
+553,254
| +49% | +$5.53M |
|
65
AnaptysBio
ANAB
$630M
| $14.7M | 0.38% |
576,600
+4,300
| +0.8% | +$110K |
|
66
Azenta
AZTA
$1.35B
| $14.2M | 0.37% |
330,200
+168,200
| +104% | +$7.21M |
|
67
Relay Therapeutics
RLAY
$709M
| $13.8M | 0.36% |
618,267
| – | – |
|
68
NovoCure
NVCR
$1.35B
| $13.3M | 0.34% |
175,000
| – | – |
|
69
Lifestance Health
LFST
$2.14B
| $13.2M | 0.34% |
2,000,000
| – | – |
|
70
Arvinas
ARVN
$580M
| $12.5M | 0.32% |
280,100
| – | – |
|
71
Compass Therapeutics
CMPX
$466M
| $12.2M | 0.31% |
5,333,188
+5,100
| +0.1% | +$11.6K |
|
72
Celldex Therapeutics
CLDX
$1.57B
| $11.9M | 0.31% |
421,604
+86,127
| +26% | +$2.42M |
|
73
Collegium Pharmaceutical
COLL
$1.25B
| $11.6M | 0.3% |
725,000
| – | – |
|
74
Amylyx Pharmaceuticals
AMLX
$877M
| $11.4M | 0.29% |
403,737
-570,370
| -59% | -$16.1M |
|
75
Novavax
NVAX
$1.2B
| $10.9M | 0.28% |
599,300
+124,200
| +26% | +$2.26M |
|